These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22220502)

  • 1. A brief survey to characterize oxycodone abuse patterns in adolescents enrolled in two substance abuse recovery high schools.
    Osgood ED; Eaton TA; Trudeau JJ; Katz NP
    Am J Drug Alcohol Abuse; 2012 Mar; 38(2):166-70. PubMed ID: 22220502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
    Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
    Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Human Abuse Potential of Oxycodone DETERx
    Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E
    J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
    Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.
    Setnik B; Roland CL; Cleveland JM; Webster L
    Pain Med; 2011 Apr; 12(4):618-31. PubMed ID: 21463474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
    Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
    Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.
    Zacny JP; Gutierrez S
    Drug Alcohol Depend; 2009 Apr; 101(1-2):107-14. PubMed ID: 19118954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
    Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
    Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
    Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
    J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
    Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
    J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.
    Cassidy TA; Oyedele N; Mickle TC; Guenther S; Budman SH
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1071-1082. PubMed ID: 28771942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
    Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
    JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
    Raffa RB; Taylor R; Pergolizzi JV
    Expert Opin Drug Saf; 2014 Feb; 13(2):181-90. PubMed ID: 24206269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.